ArticleFrontiers in public health2026
Evidence asymmetry in Australian public spending: why health alone cannot bear a higher burden of proof.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Australian Commonwealth portfolio expenditure operates under structurally asymmetric evidentiary standards that disproportionately burden the Health portfolio and distort cross-portfolio funding decisions. Despite comparable fiscal scale, Health (AU$70.8 billion projected for 2025-26) is subject to rigorous formal evaluation through mechanisms such as the Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee, while portfolios including Education (AU$72.5 billion) and Defence (AU$83.2 billion) justify expenditure predominantly through strategic alignment, narrative reporting, and performance indicators without reference to validated methodological benchmarks. This creates a paradox in which Health face greater barriers to funding than those relying on informal justificatory approaches, limiting the ability of central agencies to make transparent, comparable, and welfare-maximising funding decisions. Drawing on cross-portfolio analysis of Commonwealth Budget papers, portfolio budget statements, and central agency guidance documents, this commentary demonstrates that this asymmetry is structural rather than incidental, arising from inconsistently applied evaluative expectations that undermine efficient allocation of public resources. The Federal Government's Measuring What Matters framework explicitly endorses broader conceptions of value including wellbeing and equity, yet these remain absent from Expenditure Review Committee funding decisions, widening the gap between stated policy priorities and practice. Social Return on Investment is proposed as one potential pragmatic bridging framework capable of extending proportional evaluative standards across portfolios currently assessed through informal mechanisms, complementing established health economic methods. Aligning evidentiary standards with expenditure magnitude and societal impact requires institutional reform that makes wellbeing assessable, comparable, and consequential within budget processes, with Health well positioned to lead as a proof of concept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.